Medine.co.uk

Out of date information, search another

Venlafaxine 37.5mg Tablets

Out of date information, search another
Informations for option: Venlafaxine 37.5mg Tablets, show other option
Document: document 4 change

Version 2d1

PACKAGE LEAFLET: INFORMATION FOR THE USER Venlafaxine 37.5 mg tablets Venlafaxine

Read all of this leaflet carefully before you start taking this medicine.

-    Keep this leaflet. You may need to read it again.

-    If you have any further questions, ask your doctor or pharmacist.

-    This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.


In this leaflet:

1.    What Venlafaxine 37.5 mg is and what it is used for

2.    Before you take Venlafaxine 37.5 mg

3.    How to take Venlafaxine 37.5 mg

4.    Possible side effects

5.    How to store Venlafaxine 37.5 mg

6.    Further information

1.    WHAT Venlafaxine 37.5 mg IS AND WHAT IT IS USED FOR

Venlafaxine 37.5 mg is an antidepressant that belongs to a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). This group of medicines is used to treat depression and other conditions, such as anxiety disorders. It is thought that people who are depressed and/or anxious have lower levels of serotonin and noradrenaline in the brain. It is not fully understood how antidepressants work, but they may help by increasing the levels of serotonin and noradrenaline in the brain.

Venlafaxine 37.5 mg is a treatment for adults with depression. Treating depression properly is important to help you get better. If it is not treated, your condition may not go away and may become more serious and more difficult to treat.

2.    BEFORE YOU TAKE Venlafaxine 37.5 mg Do not take Venlafaxine 37.5 mg

   If you are allergic to venlafaxine or any of the other ingredients of Venlafaxine 37.5 mg.

   If you are also taking or have taken any time within the last 14 days any medicines known as irreversible monoamine oxidase inhibitors (MAOIs), used to treat depression or Parkinson’s disease. Taking an irreversible MAOI together with other medicines, including Venlafaxine 37.5 mg, can cause serious or even life-threatening side effects. Also, you must wait at least 7 days after you stop taking Venlafaxine 37.5 mg before you take any irreversible MAOI (see also the sections “Serotonin syndrome” and “Taking other medicines”).

Take special care with Venlafaxine 37.5 mg

   If you use other medicines that taken concomitantly with Venlafaxine 37.5 mg could increase the risk of developing serotonin syndrome (see the section “Taking other medicines”).

•    If you have eye problems, such as certain kinds of glaucoma (increased pressure in the eye).

•    If you have a history of high blood pressure.

•    If you have a history of heart problems.

•    If you have a history of fits (seizures).

•    If you have a history of low sodium levels in your blood (hyponatraemia).

•    If you have a tendency to develop bruises or a tendency to bleed easily (history of bleeding disorders), or if you are taking other medicines that may increase the risk of bleeding.

•    If your cholesterol levels get higher.

•    If you have a history of, or if someone in your family has had, mania or bipolar disorder (feeling over-excited or euphoric).

•    If you have a history of aggressive behaviour.

•    If you have diabetes.

Venlafaxine 37.5 mg may cause a sensation of restlessness or an inability to sit or stand still. You should tell your doctor if this happens to you.

If any of these conditions apply to you, please talk with your doctor before taking Venlafaxine 37.5 mg.

Thoughts of suicide and worsening of your depression or anxiety disorder

If you are depressed and/or have anxiety disorders, you can sometimes have thoughts of harming or killing yourself. These may be increased when you first start taking antidepressants, since these medicines all take time to work, usually about two weeks, but sometimes longer.

You may be more likely to think like this:

•    If you have previously had thoughts about killing yourself or harming yourself.

•    If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in young adults (less than 25 years old) with psychiatric conditions who were treated with an antidepressant.

If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.

You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.

Dry mouth

Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase the risk of caries. Therefore, you should take special care in your dental hygiene.

Use in children and adolescents under 18 years of age

Venlafaxine 37.5 mg should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side effects, such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe Venlafaxine 37.5 mg for patients under 18 because he/she decides that this is in their best interests. If your doctor has prescribed Venlafaxine 37.5 mg for a patient under 18, and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking Venlafaxine 37.5 mg. Also, the long-term safety effects concerning growth, maturation and cognitive and behavioural development of Venlafaxine 37.5 mg in this age group has not yet been demonstrated.

Taking other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Your doctor should decide whether you can take Venlafaxine 37.5 mg with other medicines.

Do not start or stop taking any medicines, including those bought without a prescription, natural and herbal remedies, before checking with your doctor or pharmacist.

•    Monoamine oxidase inhibitors (MAOIs: see the section “Before you take Venlafaxine 37.5 mg”).

•    Serotonin syndrome:

Serotonin syndrome, a potentially life-threatening condition (see the section “Possible Side Effects”), may occur with venlafaxine treatment, particularly when taken with other medicines. Examples of these medicines include:

•    Triptans (used for migraine)

•    Medicines to treat depression, for instance SNRI, SSRIs, tricyclics, or medicines containing lithium

•    Medicines containing linezolid, an antibiotic (used to treat infections)

•    Medicines containing moclobemide, a reversible MAOI (used to treat depression)

•    Medicines containing sibutramine (used for weight loss)

•    Medicines containing tramadol (a pain-killer)

•    Products containing St. John’s Wort (also called Hypericum perforatum, a natural or herbal remedy used to treat mild depression)

•    Products containing tryptophan (used for problems such as sleep and depression)

Signs and symptoms of serotonin syndrome may include a combination of the following: restlessness, hallucinations, loss of coordination, fast heart beat, increased body temperature, fast changes in blood pressure, overactive reflexes, diarrhoea, coma, nausea, vomiting. Get medical care right away if you think serotonin syndrome is happening to you.

The following medicines may also interact with Venlafaxine 37.5 mg and should be used with caution. It is especially important to mention to your doctor or pharmacist if you are taking medicines containing:

•    Ketoconazole (an antifungal medicine)

•    Haloperidol or risperidone (to treat psychiatric conditions)

•    Metoprolol (a beta blocker to treat high blood pressure and heart problems)

Taking Venlafaxine 37.5 mg with food and drink

Venlafaxine 37.5 mg should be taken with food (see section 3 “HOW TO TAKE Venlafaxine 37.5 mg”).

You should avoid alcohol while you are taking Venlafaxine 37.5 mg.

Pregnancy and breast-feeding

Tell your doctor if you become pregnant, or you are trying to become pregnant. You should use Venlafaxine 37.5 mg only after discussing the potential benefits and the potential risks to your unborn child with your doctor.

If you are taking Venlafaxine 37.5 mg during pregnancy, let your midwife and/or doctor know as your baby might have some symptoms when it is born. These symptoms usually begin during the first 24 hours after the baby is born. They include irritability, tremor, muscle weakness, constant crying, sleeping difficulties, not feeding properly and trouble with breathing. If your baby has these symptoms when it is born and you are concerned, contact your doctor and/or midwife who will be able to advise you.

Make sure your midwife and/or doctor knows you are on Venlafaxine 37.5 mg. When taken during pregnancy, similar drugs (SSRIs) may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.

Venlafaxine 37.5 mg passes into breast milk. There is a risk of an effect on the baby. Therefore, you should discuss the matter with your doctor, and he/she will decide whether you should stop breastfeeding or stop the therapy with Venlafaxine 37.5 mg.

Driving and using machines

Do not drive or use any tools or machines until you know how Venlafaxine 37.5 mg affects you.

Important information about some of the ingredients of Venlafaxine 37.5 mg

Venlafaxine tablets contain lactose. Patients with one of the following rare hereditary problems should not take this medicine: galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.

3. HOW TO TAKE Venlafaxine 37.5 mg

Always take Venlafaxine 37.5 mg exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

The usual recommended starting dose is 75 mg per day in divided doses, two or three times a day. The dose can be raised by your doctor gradually and, if needed, even up to a maximum dose of 375 mg daily for depression.

Take Venlafaxine 37.5 mg at approximately the same time each day, in the morning and in the evening.

Venlafaxine 37.5 mg should be taken with food.

If you have liver or kidney problems, talk to your doctor, since your dose of Venlafaxine 37.5 mg may need to be different.

Do not stop taking Venlafaxine 37.5 mg without talking to your doctor (see the section “If you stop taking Venlafaxine 37.5 mg").

If you take more Venlafaxine 37.5 mg than you should

Call your doctor or pharmacist immediately if you take more than the amount of Venlafaxine 37.5 mg prescribed by your doctor.

The symptoms of a possible overdose may include a rapid heart beat, changes in level of alertness (ranging from sleepiness to coma), blurred vision, seizures or fits, and vomiting.

If you forget to take Venlafaxine 37.5 mg

If you miss a dose, take it as soon as you remember. However, if it is time for your next dose, skip the missed dose and take only a single dose as usual. Do not take more than the daily amount of Venlafaxine 37.5 mg that has been prescribed for you in one day.

If you stop taking Venlafaxine 37.5 mg

Do not stop taking your treatment or reduce the dose without the advice of your doctor even if you feel better. If your doctor thinks that you no longer need Venlafaxine 37.5 mg, he/she may ask you to reduce your dose slowly, before stopping treatment altogether. Side effects are known to occur when people stop using Venlafaxine 37.5 mg, especially when Venlafaxine 37.5 mg is stopped suddenly or the dose is reduced too quickly. Some patients may experience symptoms such as tiredness, dizziness, light-headedness, headache, sleeplessness, nightmares, dry mouth, loss of appetite, nausea, diarrhoea, nervousness, agitation, confusion, ringing in the ears, tingling or rarely, electric shock sensations, weakness, sweating, seizures or flu-like symptoms.

Your doctor will advise you on how you should gradually discontinue Venlafaxine 37.5 mg treatment. If you experience any of these or other symptoms that are troublesome, ask your doctor for further advice.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Venlafaxine 37.5 mg can cause side effects, although not everybody gets them. Allergic reactions

If any of the following happen, do not take more Venlafaxine 37.5 mg. Tell your doctor immediately, or go to the casualty department at your nearest hospital:

•    Chest tightness, wheezing, trouble swallowing or breathing

•    Swelling of the face, throat, hands, or feet

•    Feeling nervous or anxious, dizziness, throbbing sensations, sudden reddening of the skin and/or a warm feeling

•    Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)

Serious side effects

If you notice any signs of the following, you may need urgent medical attention:

•    Heart problems, such as fast or irregular heart rate, increased blood pressure

•    Eye problems, such as blurred vision, dilated pupils

•    Nerve problems, such as dizziness, pins and needles, movement disorder, seizures or fits

•    Psychiatric problems, such as hyperactivity and euphoria

•    Treatment withdrawal (see the section “HOW TO TAKE Venlafaxine 37.5 mg, If you stop taking

Venlafaxine 37.5 mg")

Complete side effect listing

The frequency (likelihood of occurring) of side effects is classified as follows:

Very common

Affects more than 1 user in 10

Common

Affects 1 to 10 users in 100

Uncommon

Affects 1 to 10 users in 1,000

Rare

Affects 1 to 10 users in 10,000

Not known

Frequency cannot be estimated from the available data

Blood disorders

Uncommon:    bruising; black tarry stools (faeces) or blood in stools, which can be a sign of internal

bleeding

Not known:    reduced number of platelets in your blood, leading to an increased risk of bruising or

bleeding; blood disorders which may lead to an increased risk of infection

Metabolism/nutritional disorders

Common:    weight loss; increased cholesterol

Uncommon:    weight gain

Not known:    slight changes in blood levels of liver enzymes; decrease in blood sodium levels;

itchiness, yellow skin or eyes, dark urine, or flu-like symptoms, which are symptoms of inflammation of the liver (hepatitis); confusion, excessive water intake (known as SIADH);

abnormal breast milk production

Nervous system disorders


Very common: Common:


Uncommon:


Rare:


dry mouth; headache

abnormal dreams; decreased libido; dizziness; increased muscle tonus; insomnia; nervousness; pins and needles; sedation; tremor; confusion; feeling separated (or detached) from yourself and reality

lack of feeling or emotion; hallucinations; involuntary movement of the muscles; agitation; impaired coordination and balance

a sensation of restlessness or an inability to sit or stand still; seizures or fits; feeling overexcited or euphoric


Not known:

a high temperature with rigid muscles, confusion or agitation, and sweating, or if you experience jerky muscle movements which you can't control, these may be symptoms of serious conditions known as neuroleptic malignant syndrome; euphoric feelings, drowsiness, sustained rapid eye movement, clumsiness, restlessness, feeling of being drunk, sweating or rigid muscles, which are symptoms of serotonergic syndrome; disorientation and confusion often accompanied by hallucination (delirium); stiffness, spasms and involuntary movements of the muscles; thoughts of harming or killing yourself, vertigo, aggression

Sight and hearing disorders

Common:    blurred vision

Uncommon:    altered taste sensation; ringing in the ears (tinnitus)

Not known:    severe eye pain and decreased or blurred vision

Heart or circulation disorders

Common:    increase in blood pressure; flushing; palpitations

Uncommon: Not known:

feeling dizzy (particularly when standing up too quickly), fainting, fast heartbeat decrease in blood pressure; abnormal, rapid or irregular heart beat, which could lead to fainting

Breathing disorders

Common:    yawning

Not known:

coughing, wheezing, shortness of breath and a high temperature, which are symptoms of inflammation of the lungs associated with an increase in white blood cells (pulmonary eosinophilia)

Digestive disorders

Very common:    nausea

Common: UncommonNot known:

appetite decreased; constipation; vomiting grinding of the teeth; diarrhoea

severe abdominal or back pains (which could indicate a serious problem in the gut, liver or pancreas)

Skin disorders

Very common: UncommonNot known:

sweating (including night sweats) rash; abnormal hair loss

skin rash, which may lead to severe blistering and peeling of the skin; itching; mild rash

Muscle disorders

Not known:    unexplained muscle pain, tenderness or weakness (rhabdomyolysis)

Urinary system disorders

Common:    difficulties passing urine; increased frequency in urination

Uncommon:    inability to pass urine

Rare:    Uriniary incontinence

Reproductive and sexual disorders

Common:

abnormal ejaculation/orgasm (males); lack of orgasm; erectile dysfunction (impotence); menstrual irregularities such as increased bleeding or increased irregular bleeding

Uncommon:

abnormal orgasm (females)

General

Common:

weakness (asthenia); chills

Uncommon:    sensitivity to sunlight, general swelling of the skin especially the face, mouth,

tongue, throat area or hands and feet and/or a raised itchy rash (hives) may be present (Angioedema)

Not known:    swollen face or tongue, shortness of breath or difficulty breathing, often with skin

rashes (this may be a serious allergic reaction)

Venlafaxine 37.5 mg sometimes causes unwanted effects that you may not be aware of, such as increases in blood pressure or abnormal heart beat; slight changes in blood levels or liver enzymes, sodium or cholesterol. More rarely, Venlafaxine 37.5 mg may reduce the function of platelets in your blood, leading to an increased risk of bruising or bleeding. Therefore, your doctor may wish to do blood tests occasionally, particularly if you have been taking Venlafaxine 37.5 mg for a long time.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

5.    HOW TO STORE Venlafaxine 37.5 mg Keep out of the reach and sight of children.

Do not use Venlafaxine 37.5 mg after the expiry date, which is stated on the packaging.

This medicinal product does not require any special storage conditions

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.

6.    FURTHER INFORMATION

What Venlafaxine 37.5 mg contains

The active substance is venlafaxine.

Each tablet contains 37.5 mg venlafaxine (as hydrochloride).

The other ingredients are microcrystalline cellulose, lactose monohydrate, sodium starch glycolate (type A), magnesium stearate, yellow and brown iron oxide (E 172).

What Venlafaxine 37.5 mg looks like and contents of the pack

Beige-coloured, oval tablet.

Venlafaxine 37.5 mg is available in PVC/aluminium blister packs of 20, 28, 30, 50, 56, 60 or 100 tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

ratiopharm GmbH

Graf-Arco-Str.3

89079 Ulm

Germany

Manufacturers

Combino Pharmaceuticals SL C / Fructuos Gelabert 6-8,

08970 - Saint Joan Despi, Barcelona,

Spain

Combino Pharm Malta Ltd HF 60 HAL FAR Industrial Estate HAL FAR BBG07-Malta

Merckle GmbH Ludwig-Merckle-Strasse 3,

89143 Blaubeuren-Weiler, Germany

This leaflet was last revised in May 2011

PL 15773/0891

8